Chardan Capital Reaffirms Their Buy Rating on uniQure NV (QURE)
In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV (QURE), with a price target of $70. The company’s shares opened today at $30.12.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 19.5% and a 50.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Logicbio Therapeutics Inc, and Catalyst Biosciences Inc.
Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $66.75, implying a 121.6% upside from current levels. In a report issued on November 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $65 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $43.23 and a one-year low of $14.68. Currently, uniQure NV has an average volume of 384.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE: